About Resmed Inc
- Industry: Health Care
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.resmed.com/
Frequently Asked Questions
What is the 52-week range for RMD?
The 52-week high is $284.87 and the 52-week low is $180.265.
What is the P/E ratio for RMD?
The Price to Earnings (P/E) ratio is 20.88.
What is the dividend yield for RMD?
The indicated annual dividend yield is 1.25%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 23.88%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 26.94%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.29.
Analyst Recommendation Trends
Wall Street analyst consensus for RMD over the last few months:
Latest RMD News
2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: https://investor.resmed.comDate
Top 25 High-Growth Dividend Stocks For October 2026
October 2026 Top 25 High-Growth Dividend Stocks trading 31% below intrinsic value, with a projected 22.53% annual return. Read full analysis here.
This Stock Could Be the Big Winner Out of Oura’s IPO
Glucose monitoring company DexCom’s investment in Oura values the company at just over $5 billion. Oura is looking to go public at a valuation above $15 billion.
Is ResMed A Better Way Than Stryker To Own Medical Device Growth?
Stryker's sales have grown about 10% a year on average over the past three years, and so have ResMed's. That shared growth rate in medical devices is the bet the two have in common. Stryker (SYK) is the giant, selling hospitals everything from hip and knee products to capital equipment. ResMed is a sleep device maker with less than a quarter of Stryker's revenue. Stryker costs 32.6 times its past year's earnings, against 21.9 times for ResMed. So does Stryker's reach justify that higher price? T
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed (NYSE:RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care. Chairman and Chief Executive Officer Mick Farrell sai
ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures
ResMed Inc. (NYSE:RMD) is well positioned to benefit from the long-term growth of the global obstructive sleep apnea (OSA) treatment market. Likewise, the company remains well positioned to benefit from growing awareness and penetration in the global market, backed by a robust product portfolio. The company’s OSA portfolio includes CPAP and APAP machines, led by […]
Dividend Champion, Contender, And Challenger Highlights: Week September 20
Track weekly dividend updates for Dividend Champions, Contenders & Challengersâsee dividend changes, upcoming ex-dividend dates and pay dates here.
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
Sleep device maker ResMed rose Tuesday after the stock notched an upgrade and price target increase on Wall Street. RBC Capital analysts boosted the stock’s rating to Outperform from Sector Perform on Tuesday, while lifting the price target to $262 from $244, citing growing demand for sleep apnea devices. The firm said that ResMed a top provider of devices for respiratory care and obstructive sleep apnea (OSA), is poised to gain market share as global awareness of the condition grows.
This Analyst Just Upgraded ResMed Stock. Here's Why.
ResMed stock rallies on a bullish RBC Capital research note. Here’s why analyst Craig Wong-Pan raised his price target on RMD shares today.
Discover which S&P500 stocks are making waves on Tuesday.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)?
Earlier this year, ResMed reported quarterly results showing revenue of US$1.46 billion, up 8.6% year on year, with adjusted earnings per share ahead of expectations but accompanied by operating margin pressure from higher R&D and supply chain costs. Although the wider patient monitoring sector generally outperformed expectations, ResMed delivered the weakest revenue surprise and slowest growth among peers, raising questions about how rising expenses could affect its profitability...
ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says
ResMed (RMD) is projected to attain high-single-digit EPS growth over the next three years, despite
Wall Street Lunch: AI Regulation Hopes Fade After Trump Calls AI Concerns A 'Hoax'
While AI companies may join together to pace the frontier, traders donât think there is much chance of government regulation after President Trump pooh-poohed the idea of a robot revolution.
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.
Qorvo downgraded, Ulta Beauty upgraded: Wall Street's top analyst calls
Qorvo downgraded, Ulta Beauty upgraded: Wall Street's top analyst calls
ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ResMed Inc. (RMD) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 10:00 AM EDTCompany ParticipantsMichael Farrell - CEO &...
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More
Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold moves on names like Eli Lilly, Etsy, Northrop Grumman, and Rivian. Find out which stocks got upgraded, downgraded, or newly covered before the opening bell.
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262
RBC Capital analyst Craig Wong-Pan upgrades ResMed (NYSE:RMD) from Sector Perform to Outperform and raises the price target from $244 to $262.
Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including ResMed (NYSE:RMD) and its peers.
ResMed Stock: Is RMD Underperforming the Healthcare Sector?
ResMed has lagged behind the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.
ResMed: A Significant Upside Despite The Perceived Risk
ResMed has been de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rather than fundamentals. See why RMD stock is a Buy.
ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts
ResMed (RMD) earns a high ChartMill Dividend Rating with a sustainable 1.25% yield, 22.95% payout ratio, and top-tier profitability and health scores.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-08 | Farrell Michael J. | -4,991 | - | - |
| 2026-09-08 | Farrell Michael J. | -4,991 | $222.4385 | $1,110,191 |
| 2026-09-08 | Farrell Michael J. | +4,991 | $146.34 | $730,383 |
| 2026-09-02 | FARRELL PETER C | -970 | $234.73 | $227,688 |
| 2026-08-14 | Bloomer Aaron | +9,072 | - | - |
| 2026-08-14 | Rider Michael J | +3,230 | - | - |
| 2026-08-14 | Leong Justin | +6,461 | - | - |
| 2026-08-14 | Farrell Michael J. | +13,547 | - | - |
| 2026-08-07 | Farrell Michael J. | -4,991 | - | - |
| 2026-08-07 | Farrell Michael J. | -4,991 | $205.6895 | $1,026,596 |
| 2026-08-07 | Farrell Michael J. | +4,991 | $146.34 | $730,383 |
| 2026-08-05 | FARRELL PETER C | -8,000 | $225 | $1,800,000 |
| 2026-07-07 | Farrell Michael J. | -4,991 | - | - |
| 2026-07-07 | Farrell Michael J. | -4,991 | $218.5475 | $1,090,771 |
| 2026-07-07 | Farrell Michael J. | +4,991 | $146.34 | $730,383 |
| 2026-06-08 | Farrell Michael J. | -4,991 | - | - |
| 2026-06-08 | Farrell Michael J. | -4,991 | $193.962 | $968,064 |
| 2026-06-08 | Farrell Michael J. | +4,991 | $146.34 | $730,383 |
| 2026-06-01 | Rider Michael J | -269 | $190.57 | $51,263 |
| 2026-05-07 | Farrell Michael J. | -4,991 | - | - |
| 2026-05-07 | Farrell Michael J. | -4,991 | $207.8206 | $1,037,233 |
| 2026-05-07 | Farrell Michael J. | +4,991 | $146.34 | $730,383 |
| 2026-04-07 | Farrell Michael J. | -4,991 | - | - |
| 2026-04-07 | Farrell Michael J. | -4,991 | $225.5032 | $1,125,486 |
| 2026-04-07 | Farrell Michael J. | +4,991 | $146.34 | $730,383 |
| 2026-04-01 | Sandercock Brett | -1,000 | $224.31 | $224,310 |
| 2026-04-01 | FARRELL PETER C | -2,000 | $225 | $450,000 |
| 2026-03-09 | Farrell Michael J. | -4,991 | - | - |
| 2026-03-09 | Farrell Michael J. | -4,991 | $251.0322 | $1,252,902 |
| 2026-03-09 | Farrell Michael J. | +4,991 | $146.34 | $730,383 |
| 2026-03-04 | FARRELL PETER C | -2,000 | $260.22 | $520,440 |
| 2026-03-02 | Sandercock Brett | -1,000 | $254.3 | $254,300 |
| 2026-02-09 | Farrell Michael J. | -4,991 | - | - |
| 2026-02-09 | Farrell Michael J. | -4,991 | $273.7801 | $1,366,436 |
| 2026-02-09 | Farrell Michael J. | +4,991 | $146.34 | $730,383 |
| 2026-02-04 | Rider Michael J | -50 | $260 | $13,000 |
| 2026-02-04 | FARRELL PETER C | -2,000 | $251.31 | $502,620 |
| 2026-02-02 | Sandercock Brett | -1,000 | $257.03 | $257,030 |
| 2026-01-07 | FARRELL PETER C | -2,000 | $248.83 | $497,660 |
| 2026-01-07 | Farrell Michael J. | -4,991 | - | - |
| 2026-01-07 | Farrell Michael J. | -4,991 | $248.4603 | $1,240,065 |
| 2026-01-07 | Farrell Michael J. | +4,991 | $146.34 | $730,383 |
| 2026-01-02 | Rider Michael J | -50 | $241.75 | $12,088 |
| 2026-01-02 | Sandercock Brett | -1,000 | $241.75 | $241,750 |
| 2025-12-08 | Farrell Michael J. | -4,991 | - | - |
| 2025-12-08 | Farrell Michael J. | -4,991 | $251.4117 | $1,254,796 |
| 2025-12-08 | Farrell Michael J. | +4,991 | $146.34 | $730,383 |
| 2025-12-03 | FARRELL PETER C | -2,000 | $251.47 | $502,940 |
| 2025-12-01 | Rider Michael J | -50 | $244.16 | $12,208 |
| 2025-12-01 | Sandercock Brett | -1,000 | $244.16 | $244,160 |
| 2025-11-25 | De Witte Jan | -2,055 | $255 | $524,025 |
| 2025-11-24 | Mowad-Nassar Nicole | +1,331 | $250.52 | $333,442 |
| 2025-11-24 | Farrell Michael J. | +33,288 | $250.52 | $8,339,310 |
| 2025-11-24 | FARRELL PETER C | +1,331 | $250.52 | $333,442 |
| 2025-11-20 | Mowad-Nassar Nicole | +536 | - | - |
| 2025-11-20 | Hernandez John | +1,073 | - | - |
| 2025-11-20 | Tan Desney | +1,073 | - | - |
| 2025-11-20 | DelOrefice Christopher | +1,073 | - | - |
| 2025-11-20 | Leong Justin | +1,848 | - | - |
| 2025-11-20 | De Witte Jan | +1,073 | - | - |
| 2025-11-20 | Gill Harjit | +1,073 | - | - |
| 2025-11-20 | Drexler Karen | +1,073 | - | - |
| 2025-11-20 | Burt Carol | +1,073 | - | - |
| 2025-11-20 | Farrell Michael J. | -7,297 | - | - |
| 2025-11-20 | Farrell Michael J. | +13,551 | - | - |
| 2025-11-20 | Sandercock Brett | +2,710 | - | - |
| 2025-11-20 | FARRELL PETER C | +536 | - | - |
| 2025-11-20 | TAYLOR RONALD R | +1,073 | - | - |
| 2025-11-14 | FARRELL PETER C | -11,442 | - | - |
| 2025-11-14 | FARRELL PETER C | -7,314 | $244.46 | $1,787,980 |
| 2025-11-14 | FARRELL PETER C | +11,442 | $101.64 | $1,162,965 |
| 2025-11-12 | FARRELL PETER C | -2,000 | $252.05 | $504,100 |
| 2025-11-11 | Gill Harjit | -38 | $250.1 | $9,504 |
| 2025-11-11 | Rider Michael J | -501 | $250.1 | $125,300 |
| 2025-11-11 | Rider Michael J | -715 | $250.1 | $178,822 |
| 2025-11-11 | Rider Michael J | -174 | $250.1 | $43,517 |
| 2025-11-11 | Rider Michael J | -135 | $250.1 | $33,764 |
| 2025-11-11 | De Witte Jan | -76 | $250.1 | $19,008 |
| 2025-11-11 | De Witte Jan | -487 | $250.25 | $121,872 |
| 2025-11-11 | Farrell Michael J. | -2,206 | $250.1 | $551,721 |
| 2025-11-11 | Farrell Michael J. | -3,459 | $250.1 | $865,096 |
| 2025-11-11 | Farrell Michael J. | -2,232 | $250.1 | $558,223 |
| 2025-11-11 | FARRELL PETER C | -163 | $250.1 | $40,766 |
| 2025-11-07 | Farrell Michael J. | -7,028 | - | - |
| 2025-11-07 | Farrell Michael J. | -983 | - | - |
| 2025-11-07 | Farrell Michael J. | -8,011 | $249.7532 | $2,000,773 |
| 2025-11-07 | Farrell Michael J. | +7,028 | $101.64 | $714,326 |
| 2025-11-07 | Farrell Michael J. | +983 | $101.64 | $99,912 |
| 2025-11-03 | Sandercock Brett | -2,000 | - | - |
| 2025-11-03 | Sandercock Brett | -3,000 | $247.54 | $742,620 |
| 2025-11-03 | Sandercock Brett | +2,000 | $101.64 | $203,280 |
| 2025-10-07 | Farrell Michael J. | -8,009 | - | - |
| 2025-10-07 | Farrell Michael J. | -8,009 | $282.8483 | $2,265,332 |
| 2025-10-07 | Farrell Michael J. | +8,009 | $101.64 | $814,035 |